title: Intranodal injection of anticancer drugs into fixed cervical metastatic lymph nodes.
abstract: OBJECTIVE
  In patients with head and neck carcinoma, fixed enlarged metastatic lymph nodes (LNs) are sometimes inoperable and carry an increased risk of mortality. To control metastatic LNs, we attempted intranodal injection of anticancer agents.
  
  
  METHODS
  Fifteen patients with squamous cell carcinoma arising in the gingiva (8), tongue (3), floor of the mouth (1), or maxillary sinus (3) were enrolled. These patients consisted of two groups, those in the early era in which the fixed LNs of six patients were treated with 60Co (RA group) and those in the late era in which both radiation and intranodal injection of anticancer agents were administered to nine patients (IN group). Intranodal injection consisted of peplomycin, 5-fluorouracil, and cis-diamminedichloroplatinum.
  
  
  RESULTS
  In the IN group, LNs regressed from about 40% to nearly 100%, although two patients showed no appreciable response. The LNs treated by combination therapy regressed considerably while LNs in the same patients treated with 60Co alone showed a minor response or grew gradually. In three patients, the LNs regressed sufficiently to be extirpated safely. The good clinical response in the locally injected LNs was histologically associated with distinct evidence of tumor cell degeneration. In the RA group, none of the LNs responded to radiation with 60Co; one LN exhibited slight regression, but the others enlarged during and soon after the radiation. Compatible with the clinical effects, many patients in the IN group demonstrated a good prognosis; three are alive without disease, and four survived for prolonged periods. However, all patients in the RA group died due to progression of the positive LNs or pulmonary complication within 10 months.
  
  
  CONCLUSIONS
  These results indicate that intranodal injection of anticancer drugs is useful for the management of fixed enlarged LNs.
authors.affiliation: Department of Oral Surgery, Kochi Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Osaki
authors.forename: E
authors.initials: E
authors.lastname: Ueta
authors.forename: K
authors.initials: K
authors.lastname: Yoneda
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007272:Injections, Intralymphatic; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000473:pathology; D009333:Neck; D018579:Patient Selection; D017663:Peplomycin / Q000008:administration & dosage; D012468:Salivary Gland Neoplasms / Q000473:pathology
chemical_list: D017663:Peplomycin; D002945:Cisplatin; D005472:Fluorouracil